Atara Biotherapeutics, Inc. (ATRA)
NASDAQ
8.59
-0.84 (-8.91%)
Closed
Oct 23, 2026
Day's Range
8.559.37
52 wk Range
3.9219.14
Financial Statements - ATRA - Atara Biotherapeutics, Inc.
Revenue
120.77M▼ 6.3%
Net Income
32.68M▲ 138.3%Net Margin 27.1%
EBITDA
38.62M▲ 151.0%
Free Cash Flow
-50.94M▲ 26.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M | 0 |
| Cost of Goods | 21.21M | 21M | 8.88M | 0 | - | - |
| Gross Profit | 99.56M | 107.93M | -313K | 63.57M | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 35.86M | -83.43M | -276M | -280.51M | -340.46M | -309.05M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -34K | 528K | -246K | 49.53M | - | - |
| Pre Tax Income | 32.71M | -85.41M | -276.11M | -228.29M | -340.09M | -306.60M |
| Income Tax | 31K | -12K | 15K | 12K | 46K | 15K |
| Net Income | 32.68M | -85.40M | -276.12M | -228.30M | -340.14M | -306.62M |
| EPS Basic | 2.61 | -11.41 | -65.25 | -56 | -90.75 | -103.75 |
| EPS Diluted | 2.57 | -11.41 | -65.25 | -56 | -90.75 | -103.75 |
| Basic Shares Outstanding | 12.54M | 7.48M | 4.23M | 4.07M | 3.74M | 2.95M |
| Diluted Shares Outstanding | 12.54M | 7.48M | 4.23M | 4.07M | 3.74M | 2.95M |
| Ebit | 36.51M | -80.80M | -270.82M | -227.91M | -340.46M | -309.05M |
| Ebitda | 38.62M | -75.74M | -265.99M | -272.50M | -331.11M | -300.72M |
| Net Income Continuous Operations | 32.68M | -85.40M | -276.12M | -228.30M | -340.14M | -306.62M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
